



# 2021 Complex General Surgical Oncology: All References

Below you will find the topics and their accompanying references for the 2021 Complex General Surgical Oncology Continuous Certification Assessment. References that are available open source are indicated with a green star ★ and the entire citation is a link to the open access source. References that are not available open access have a link in their PubMed ID to the abstract.

Diplomates are neither required nor expected to read all of these references before or during the completion of the assessment.

## Anorectal Neoplasms

- ★ [You YN, Hardiman KM, Bafford A, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. \*Dis Colon Rectum\*. 2020;63\(9\):1191-1222.](#)  
[PMID: 33216491]
- Ross H, Steele SR, Varma M, et al. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum*. 2014;57(1):5-22.  
[PMID: 24316941]
- ★ [Shaukat A, Kaltenbach T, Dominitz JA, et al. Endoscopic recognition and management strategies for malignant colorectal polyps: recommendations of the US Multi-Society Task Force on Colorectal Cancer. \*Gastroenterology\*. 2020;159\(5\):1916-1934.e2.](#)  
[PMID: 33159840]
- Pedraza R, Siddharthan R. Management of malignant colon polyps. *Dis Colon Rectum*. 2021;64(3):262-266.  
[PMID: 33337601]
- ★ [Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of colorectal metastases. \*Cancer\*. 2020;126\(11\):2534-2540.](#)  
[PMID: 32282070]
- ★ [Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases \(PRODIGE 7\): a multicentre, randomised, open-label, phase 3 trial. \*Lancet Oncol\*. 2021;22\(2\):256-266.](#)  
[PMID: 33476595]

## Appendiceal Neoplasms

- ★ [Glasgow SC, Gaertner W, Stewart D, et al. The American Society of Colon and Rectal Surgeons, clinical practice guidelines for the management of appendiceal neoplasms. \*Dis Colon Rectum\*. 2019;62\(12\):1425-1438.](#)  
[PMID: 31725580]



# 2021 Complex General Surgical Oncology: All References

## Breast Cancer

- ★ [Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. \*J Natl Cancer Inst.\* 2013;105\(21\):1607-1616.](#)  
[PMID: 24136893]
- ★ [Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. \*J Med Genet.\* 2013;50\(4\):255-263.](#)  
[PMID: 23335809]
- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Breast Cancer. Version 5.2021 - June 28, 2021.](#)
- [Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. \*J Clin Oncol.\* 1997;15\(6\):2345-2350.](#)  
[PMID: 9196149]
- ★ [Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. \*Ann Surg Oncol.\* 2014;21\(3\):704-716.](#)  
[PMID: 24515565]
- ★ [Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx. \*J Clin Oncol.\* 2019;37\(22\):1956-1964.](#)  
[PMID: 31150316]
- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Breast Cancer. Version 5.2021 - June 28, 2021.](#)
- ★ [Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the american society of breast surgeons. \*Ann Surg Oncol.\* 2019;26\(10\):3025-3031.](#)  
[PMID: 31342359]
- ★ [Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. \*J Clin Oncol.\* 2005;23\(12\):2694-2702.](#)  
[PMID: 15837984]
- ★ [Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. \*J Clin Oncol.\* 2015;33\(3\):258-264.](#)  
[PMID: 25452445]
- ★ [von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. \*N Engl J Med.\* 2019;380\(7\):617-628.](#)  
[PMID: 30516102]



# 2021 Complex General Surgical Oncology: All References

## Clinical Trial Design

- ★ [Yeh J, Gupta S, Patel SJ, Kota V, Guddati AK. Trends in the crossover of patients in phase III oncology clinical trials in the USA. \*Ecancermedicalscience\*. 2020;14:1142.](#)  
[PMID: 33343701]
- ★ [Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. \*Postgrad Med\*. 2011;123\(5\):194-204.](#)  
[PMID: 21904102]
- ★ [Haslam A, Prasad V. When is crossover desirable in cancer drug trials and when is it problematic? \*Ann Oncol\*. 2018;29\(5\):1079-1081.](#)  
[PMID: 29648572]

## Colorectal Liver Metastases

- ★ [Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer \(FOXFIRE, SIRFLOX, and FOXFIRE-Global\): a combined analysis of three multicentre, randomised, phase 3 trials. \*Lancet Oncol\*. 2017;18\(9\):1159-1171.](#)  
[PMID: 28781171]
- ★ [Buisman FE, Galjart B, van der Stok EP, et al. Recurrence patterns after resection of colorectal liver metastasis are modified by perioperative systemic chemotherapy. \*World J Surg\*. 2020;44\(3\):876-886.](#)  
[PMID: 31410513]
- [Ignatavicius P, Oberkofler CE, Chapman WC, et al. Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: a throw of the dice? \*Ann Surg\*. 2020;272\(5\):715-722.](#)  
[PMID: 32833764]
- [Viganò L, Procopio F, Cimino MM, et al. Is tumor detachment from vascular structures equivalent to R0 resection in surgery for colorectal liver metastases? an observational cohort. \*Ann Surg Oncol\*. 2016;23\(4\):1352-1360.](#)  
[PMID: 26714946]

## Desmoid Tumors

- ★ [Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. \*Ann Surg\*. 2013;258\(2\):347-353.](#)  
[PMID: 23532110]
- ★ [Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. \*Eur J Cancer\*. 2020;127:96-107.](#)  
[PMID: 32004793]



## 2021 Complex General Surgical Oncology: All References

- ★ [Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. \*N Engl J Med\*. 2018;379\(25\):2417-2428.](#)  
[PMID: 30575484]

### End of Life Issues

- Medical futility in end-of-life care: report of the Council on Ethical and Judicial Affairs. *JAMA*. 1999;281(10):937-941.  
[PMID: 10078492]
- ★ [Chiarchiaro J, Buddadhumaruk P, Arnold RM, White DB. Quality of communication in the ICU and surrogate's understanding of prognosis. \*Crit Care Med\*. 2015;43\(3\):542-548.](#)  
[PMID: 25687030]
- ★ [White DB, Ernecoff N, Buddadhumaruk P, et al. Prevalence of and factors related to discordance about prognosis between physicians and surrogate decision makers of critically ill patients. \*JAMA\*. 2016;315\(19\):2086-2094.](#)  
[PMID: 27187301]
- ★ [McCabe MS, Storm C. When doctors and patients disagree about medical futility. \*J Oncol Pract\*. 2008;4\(4\):207-209.](#)  
[PMID: 20856774]

### Gastric Cancer

- ★ [Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. \*Lancet Oncol\*. 2020;21\(8\):e386-e397.](#)  
[PMID: 32758476]

### Gastroesophageal Cancer

- ★ [van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. \*N Engl J Med\*. 2012;366\(22\):2074-2084.](#)  
[PMID: 22646630]
- ★ [Rice TW, Ishwaran H, Blackstone EH, et al. Recommendations for clinical staging \(cTNM\) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. \*Dis Esophaqus\*. 2016;29\(8\):913-919.](#)  
[PMID: 27905171]
- ★ [Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma \(FLOT4\): a randomised, phase 2/3 trial. \*Lancet\*. 2019;393\(10184\):1948-1957.](#)  
[PMID: 30982686]



## 2021 Complex General Surgical Oncology: All References

- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Esophageal and Esophagogastric Junction Cancers. Version 4.2021 - August 3, 2021.](#)
- Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. *N Engl J Med.* 2021;384(13):1191-1203. [PMID: 33789008]
- ★ [Gasparri MG, Tisol WB, Haasler GB. Roux-en-Y diversion for debilitating reflux after esophagectomy. \*Am Surg.\* 2005;71\(8\):687-689.](#) [PMID: 16217953]
- ★ [Yano M, Sugimura K, Miyata H, et al. Randomized comparison of gastric tube reconstruction with and without duodenal diversion plus Roux-en-Y anastomosis after esophagectomy. \*Ann Surg.\* 2020;272\(1\):48-54.](#) [PMID: 31415003]

### Gastrointestinal Stromal Tumors

- Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet.* 2006;368(9544):1329-1338. [PMID: 17046465]
- ★ [Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib \(GRID\): an international, multicentre, randomised, placebo-controlled, phase 3 trial. \*Lancet.\* 2013;381\(9863\):295-302.](#) [PMID: 23177515]
- ★ [Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour \(NAVIGATOR\): a multicentre, open-label, phase 1 trial. \*Lancet Oncol.\* 2020;21\(7\):935-946.](#) [PMID: 32615108]
- ★ [Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. \*Ann Oncol.\* 2018;29\(suppl 4\):iv68-iv78.](#) [PMID: 29846513]
- ★ [Cavnar MJ, Wang L, Balachandran VP, et al. Rectal gastrointestinal stromal tumor \(GIST\) in the era of imatinib: organ preservation and improved oncologic outcome. \*Ann Surg Oncol.\* 2017;24\(13\):3972-3980.](#) [PMID: 29058144]
- ★ [Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour \(NAVIGATOR\): a multicentre, open-label, phase 1 trial. \*Lancet Oncol.\* 2020;21\(7\):935-946.](#) [PMID: 32615108]



## 2021 Complex General Surgical Oncology: All References

- ★ [Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours \(INVICTUS\): a double-blind, randomised, placebo-controlled, phase 3 trial. \*Lancet Oncol.\* 2020;21\(7\):923-934.](#)  
[PMID: 32511981]
- ★ [von Mehren M. Management of gastrointestinal stromal tumors. \*Surg Clin North Am.\* 2016;96\(5\):1059-1075.](#)  
[PMID: 27542643]
- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Gastrointestinal Stromal Tumors \(GISTs\). Version 1.2021 - October 30, 2020.](#)
- ★ [Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. \*N Engl J Med.\* 2002;347\(7\):472-480.](#)  
[PMID: 12181401]

### Hepatocellular Carcinoma

- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Hepatobiliary Cancers. Version 3.2021 – June 15, 2021.](#)
- ★ [Squires MH 3rd, Hanish SI, Fisher SB, et al. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. \*J Surg Oncol.\* 2014;109\(6\):533-541.](#) [PMID: 24347475]

### Hepato-Pancreato-Biliary Cancer

- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Pancreatic Adenocarcinoma. Version 2.2021 – February 25, 2021.](#)
- Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. *Ann Surg Oncol.* 2009;16(7):1727-1733.  
[PMID: 19396496]
- Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. *Ann Surg Oncol.* 2013;20(7):2188-2196.  
[PMID: 23247983]
- ★ [Reni M. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? \*World J Gastroenterol.\* 2010;16\(39\):4883-4887.](#)  
[PMID: 20954273]
- ★ [Lim KH, Chung E, Khan A, et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? \*Oncologist.\* 2012;17\(2\):192-200.](#)  
[PMID: 22250057]



# 2021 Complex General Surgical Oncology: All References

## Hyperaldosteronism

- ★ [Rossi GP, Maiolino G, Seccia TM. Adrenal venous sampling: where do we stand? \*Endocrinol Metab Clin North Am.\* 2019;48\(4\):843-858.](#)  
[PMID: 31655780]
- [Kempers MJ, Lenders JW, van Outheusden L, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. \*Ann Intern Med.\* 2009;151\(5\):329-337.](#)  
[PMID: 19721021]
- ★ [Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. \*Endocr Pract.\* 2009;15\(suppl 1\):1-20.](#)  
[PMID: 19632967]
- ★ [Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. \*Hypertension.\* 2014;63\(1\):151-160.](#)  
[PMID: 24218436]

## Melanoma

- ★ [Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma \(OpACIN-neo\): a multicentre, phase 2, randomised, controlled trial. \*Lancet Oncol.\* 2019;20\(7\):948-960.](#)  
[PMID: 31160251]
- [Spillane AJ, Menzies AM, van Akkooi ACJ. The Landmark Series: neoadjuvant systemic therapy \(NAST\) for stage 3 melanoma patients - a potential paradigm shift in management. \*Ann Surg Oncol.\* 2020;27\(7\):2188-2200.](#)  
[PMID: 32409966]
- ★ [Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma \(NeoCombi\): a single-arm, open-label, single-centre, phase 2 trial. \*Lancet Oncol.\* 2019;20\(7\):961-971.](#)  
[PMID: 31171444]
- ★ [Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. \*N Engl J Med.\* 2020;383\(12\):1139-1148.](#)  
[PMID: 32877599]
- ★ [Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. \*N Engl J Med.\* 2018;378\(19\):1789-1801.](#)  
[PMID: 29658430]
- ★ [Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. \*N Engl J Med.\* 2017;377\(19\):1824-1835.](#)  
[PMID: 28891423]



## 2021 Complex General Surgical Oncology: All References

- ★ [Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. \*N Engl J Med.\* 2016;375\(19\):1845-1855.](#)  
[PMID: 27717298]
- ★ [Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. \*N Engl J Med.\* 2017;376\(23\):2211-2222.](#)  
[PMID: 28591523]
- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Melanoma: Cutaneous. Version 2.2021 - February 19, 2021.](#)
- ★ [Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma \(DeCOG-SLT\): a multicentre, randomised, phase 3 trial. \*Lancet Oncol.\* 2016;17\(6\):757-767.](#)  
[PMID: 27161539]
- ★ [Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. \*N Engl J Med.\* 2014;370\(7\):599-609.](#)  
[PMID: 24521106]
- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Melanoma: Cutaneous. Version 2.2021 - February 19, 2021.](#)
- ★ [Deckers EA, Hoekstra-Weebers JEHM, Damude S, et al. The MELFO study: a multicenter, prospective, randomized clinical trial on the effects of a reduced stage-adjusted follow-up schedule on cutaneous melanoma IB-IIC patients-results after 3 years. \*Ann Surg Oncol.\* 2020;27\(5\):1407-1417.](#)  
[PMID: 31535302]
- Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. *Ann Surg Oncol.* 2009;16(3):571-577.  
[PMID: 19030934]
- ★ [Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. \*Ann Surg Oncol.\* 2008 Aug;15\(8\):2206-14.](#)  
[PMID: 18512102]
- ★ [Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. \*N Engl J Med.\* 2017;376\(23\):2211-2222.](#)  
[PMID: 28591523]
- ★ [Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma \(DeCOG-SLT\): a multicentre, randomised, phase 3 trial. \*Lancet Oncol.\* 2016;17\(6\):757-767.](#)  
[PMID: 27161539]





# 2021 Complex General Surgical Oncology: All References

## Neuroendocrine Tumors

- ★ [Sallinen V, Le Large TY, Galeev S, et al. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis. \*HPB \(Oxford\)\*. 2017;19\(4\):310-320.](#)  
[PMID: 28254159]
- ★ [Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. \*Neuroendocrinology\*. 2016;103\(2\):153-171.](#)  
[PMID: 26742109]
- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Neuroendocrine and Adrenal Tumors. Version 2.2021 – June 18, 2021.](#)
- ★ [Partelli S, Mazza M, Andreasi V, et al. Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: limitations to apply guidelines into real life. \*Surgery\*. 2019;166\(2\):157-163.](#)  
[PMID: 31109657]

## Pancreatic Cancer

- ★ [Chatzizacharias NA, Tsai S, Griffin M, et al. Locally advanced pancreas cancer: staging and goals of therapy. \*Surgery\*. 2018;163\(5\):1053-1062.](#)  
[PMID: 29331400]
- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Pancreatic Adenocarcinoma. Version 2.2021 - February, 2021.](#)

## Peritoneal Surface Malignancies

- ★ Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms. *Ann Surg Oncol*. 2020;27(6):1753-1760.  
[PMID: 32285275]
- ★ Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. *Ann Surg Oncol*. 1999;6(8):727-731.  
[PMID: 10622499]

## Pheochromocytoma

- Buffet A, Venisse A, Nau V, et al. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. *Horm Metab Res*. 2012;44(5):359-366.  
[PMID: 22517557]



## 2021 Complex General Surgical Oncology: All References

- ★ [Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. \*J Clin Endocrinol Metab.\* 2014;99\(6\):1915-1942. \[PMID: 24893135\]](#)
- ★ [Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. \*J Clin Endocrinol Metab.\* 2014;99\(6\):1915-1942. \[PMID: 24893135\]](#)
- ★ [Lefebvre M, Foulkes WD. Pheochromocytoma and paraganglioma syndromes: genetics and management update. \*Curr Oncol.\* 2014;21\(1\):e8-e17. \[PMID: 24523625\]](#)

### Retroperitoneal Sarcoma

- Tseng WW, Barretta F, Conti L, et al. Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. *Cancer.* 2021;127(5):729-738. [PMID: 33206381]
- ★ [Miura JT, Charlson J, Gamblin TC, et al. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. \*Eur J Surg Oncol.\* 2015;41\(10\):1386-1392. \[PMID: 26251340\]](#)
- ★ [Nussbaum DP, Rushing CN, Lane WO, et al. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. \*Lancet Oncol.\* 2016;17\(7\):966-975. \[PMID: 27210906\]](#)
- ★ [Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma \(EORTC-62092: STRASS\): a multicentre, open-label, randomised, phase 3 trial. \*Lancet Oncol.\* 2020;21\(10\):1366-1377. \[PMID: 32941794\]](#)

### Squamous Cell Carcinoma

- ★ [Stewart DB, Gaertner WB, Glasgow SC, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for anal squamous cell cancers \(revised 2018\). \*Dis Colon Rectum.\* 2018;61\(7\):755-774. \[PMID: 29878949\]](#)
- Severino NP, Chadi SA, Rosen L, et al. Survival following salvage abdominoperineal resection for persistent and recurrent squamous cell carcinoma of the anus: do these disease categories affect survival? *Colorectal Dis.* 2016;18(10):959-966. [PMID: 26850085]
- ★ [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\): Anal Carcinoma. Version 2.2021 – June 30, 2021.](#)



## Thyroid Cancer

- ★ [Rondeau G, Fish S, Hann LE, Fagin JA, Tuttle RM. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. \*Thyroid\*. 2011;21\(8\):845-853.](#)  
[PMID: 21809914]
- ★ [Robenshtok E, Fish S, Bach A, Domínguez JM, Shaha A, Tuttle RM. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. \*J Clin Endocrinol Metab\*. 2012;97\(8\):2706-2713.](#)  
[PMID: 22639292]
- [Park S, Kim WG, Song E, et al. Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy. \*Thyroid\*. 2017;27\(4\):524-530.](#)  
[PMID: 27869547]
- ★ [Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults. \*Ann Surg\*. 2020;271\(3\):e21-e93.](#)  
[PMID: 32079830]
- ★ [Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. \*Thyroid\*. 2016;26\(1\):1-133.](#)  
[PMID: 26462967]
- ★ [Haddad RI, Nasr C, Bischoff L, et al. NCCN Guidelines insights: thyroid carcinoma, version 2.2018. \*J Natl Compr Canc Netw\*. 2018;16\(12\):1429-1440.](#)  
[PMID: 30545990]
- ★ [Jayarangaiah A, Sidhu G, Brown J, et al. Therapeutic options for advanced thyroid cancer. \*Int J Clin Endocrinol Metab\*. 2019;5\(1\):26-34.](#)  
[PMID: 31709422]
- ★ [Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. \*J Clin Oncol\*. 2018;36\(1\):7-13.](#)  
[PMID: 29072975]
- ★ [Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer. \*Thyroid\*. 2021;31\(3\):337-386.](#)  
[PMID: 33728999]